Table 2. Demographics of study participants.
| Reference | Cell therapy |
|
|---|---|---|
| Recipient age | ||
| Mean | 48 | 47 |
| Median (range) | 46 (31–67) | 44 (28–69) |
| Sex (n) | ||
| Male (%) | 14 (74) | 10 (83) |
| Female (%) | 5 (26) | 2 (17) |
| Ethnicity (n) | ||
| White (%) | 15 (79) | 10 (83) |
| Asian (%) | 4 (21) | 1 (8) |
| Black (%) | 0 | 1 (8) |
| Primary renal disease (n) | ||
| APKD (%) | 5 (26) | 3 (25) |
| Glomerulonephritis (%) | 7 (37) | 4 (33) |
| Urological (%) | 3 (16) | 1 (8) |
| Other (%) | 4 (21) | 4 (33) |
| RRT (n) | ||
| HD (%) | 5 (26) | 3 (25) |
| PD (%) | 5 (26) | 0 |
| Pre-emptive (%) | 9 (47) | 9 (75) |
| Donor age | ||
| Mean | 56 | 45 |
| Median (range) | 59 (32–68) | 45 (28–71) |
| Donor relationship (n) | ||
| Living related (%) | 15 (79) | 6 (50) |
| Living unrelated (%) | 4 (21) | 6 (50) |
| Mismatches (n) | ||
| 1–2 (%) | 9 (47) | 5 (42) |
| 3–4 (%) | 8 (42) | 6 (50) |
| 5–6 (%) | 2 (11) | 1 (8) |
| PRA baseline (n) | ||
| 0 (%) | 16 (84) | 10 (83) |
| <10 (%) | 2 (11) | 2 (16) |
| 10–30 (%) | 1 (5) | 0 (0) |
| CMV status (n) | ||
| Donor – recipient – (%) | 2 (11) | 3 (25) |
| Donor – recipient + (%) | 4 (21) | 5 (42) |
| Donor + recipient + (%) | 10 (53) | 1 (8) |
| Donor + recipient – (%) | 3 (16) | 3 (25) |
Abbreviations: APKD, adult polycystic kidney disease; CMV, cytomegalovirus; HD, hemodialysis; PD, peritoneal dialysis; PRA, panel reactive antibody; RRT, renal replacement therapy.